These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33275150)

  • 1. Estimated Cost-effectiveness of Newborn Screening for Congenital Cytomegalovirus Infection in China Using a Markov Model.
    Chen K; Zhong Y; Gu Y; Sharma R; Li M; Zhou J; Wu Y; Gao Y; Qin G
    JAMA Netw Open; 2020 Dec; 3(12):e2023949. PubMed ID: 33275150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection.
    Gantt S; Dionne F; Kozak FK; Goshen O; Goldfarb DM; Park AH; Boppana SB; Fowler K
    JAMA Pediatr; 2016 Dec; 170(12):1173-1180. PubMed ID: 27723885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of Congenital Cytomegalovirus Infection to Permanent Hearing Loss in a Highly Seropositive Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study.
    Yamamoto AY; Anastasio ART; Massuda ET; Isaac ML; Manfredi AKS; Cavalcante JMS; Carnevale-Silva A; Fowler KB; Boppana SB; Britt WJ; Mussi-Pinhata MM
    Clin Infect Dis; 2020 Mar; 70(7):1379-1384. PubMed ID: 31102409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Targeted Screening Program for Congenital Cytomegalovirus Infection in Infants Who Fail Newborn Hearing Screening.
    Vancor E; Shapiro ED; Loyal J
    J Pediatric Infect Dis Soc; 2019 Mar; 8(1):55-59. PubMed ID: 29373759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal newborn screening for congenital cytomegalovirus infection: feasibility and relevance in a French type-III maternity cohort.
    Letamendia-Richard E; Périllaud-Dubois C; de La Guillonnière L; Thouard I; Cordier AG; Roque-Afonso AM; de Luca D; Benachi A; Vauloup-Fellous C
    BJOG; 2022 Jan; 129(2):291-299. PubMed ID: 34726316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of screening infants at risk of hearing impairment: an international analysis.
    Burke MJ; Shenton RC; Taylor MJ
    Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of targeted screening for congenital cytomegalovirus in newborns compared to clinical diagnosis in the US.
    Phillips VL; Xu J; Park A; Gantt S; Dedhia K
    Int J Pediatr Otorhinolaryngol; 2023 Mar; 166():111450. PubMed ID: 36773448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
    Puttarajappa CM; Hariharan S; Smith KJ
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):290-298. PubMed ID: 29025787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of neonatal hearing screening program in China: should universal screening be prioritized?
    Huang LH; Zhang L; Tobe RY; Qi FH; Sun L; Teng Y; Ke QL; Mai F; Zhang XF; Zhang M; Yang RL; Tu L; Li HH; Gu YQ; Xu SN; Yue XY; Li XD; Qi BE; Cheng XH; Tang W; Xu LZ; Han DM
    BMC Health Serv Res; 2012 Apr; 12():97. PubMed ID: 22510223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn hearing screening: the great omission.
    Mehl AL; Thomson V
    Pediatrics; 1998 Jan; 101(1):E4. PubMed ID: 9417168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonates with congenital Cytomegalovirus and hearing loss identified via the universal newborn hearing screening program.
    Rawlinson WD; Palasanthiran P; Hall B; Al Yazidi L; Cannon MJ; Cottier C; van Zuylen WJ; Wilkinson M
    J Clin Virol; 2018 May; 102():110-115. PubMed ID: 29571077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of long-term impacts of universal newborn hearing screening.
    Chiou ST; Lung HL; Chen LS; Yen AM; Fann JC; Chiu SY; Chen HH
    Int J Audiol; 2017 Jan; 56(1):46-52. PubMed ID: 27598544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection.
    Bergevin A; Zick CD; McVicar SB; Park AH
    Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2090-3. PubMed ID: 26432541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection.
    Williams EJ; Gray J; Luck S; Atkinson C; Embleton ND; Kadambari S; Davis A; Griffiths P; Sharland M; Berrington JE; Clark JE
    Arch Dis Child Fetal Neonatal Ed; 2015 Nov; 100(6):F501-6. PubMed ID: 26122458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of congenital CMV infection via DBS samples testing and neonatal hearing screening: an observational study in Italy.
    Pellegrinelli L; Galli C; Primache V; Alde' M; Fagnani E; Di Berardino F; Zanetti D; Pariani E; Ambrosetti U; Binda S
    BMC Infect Dis; 2019 Jul; 19(1):652. PubMed ID: 31331274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of maternal and neonatal screening for congenital cytomegalovirus infection in Japan.
    Aoki H; Bitnun A; Kitano T
    J Med Virol; 2023 Jan; 95(1):e28391. PubMed ID: 36484373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected cost-effectiveness of statewide universal newborn hearing screening.
    Keren R; Helfand M; Homer C; McPhillips H; Lieu TA
    Pediatrics; 2002 Nov; 110(5):855-64. PubMed ID: 12415021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a national neonatal hearing screening program in China: conditions for the scale-up.
    Tobe RG; Mori R; Huang L; Xu L; Han D; Shibuya K
    PLoS One; 2013; 8(1):e51990. PubMed ID: 23341887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).
    Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M
    Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.